Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03107416 · ClinicalTrials.gov registry record · Phase 1
Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells
A Phase 1 study of Unresectable Hepatocellular Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 1
- Development phase
- 30
- Enrollment target
- 5
- Study locations
NCT03107416: Active Phase 1 study of Unresectable Hepatocellular Carcinoma, sponsored by Memorial Sloan Kettering Cancer Center.
NCT03107416 is a Phase 1 study of Unresectable Hepatocellular Carcinoma that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 30 participants, below the 84-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (64% lower). The trial reports 5 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03107416, a Phase 1 study of Unresectable Hepatocellular Carcinoma, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 30 participants
- Enrollment target
- 5
- Study locations
Study Summary
The purpose of this study is to test the safety of Bumetanide , at different doses to find out what effects, if any, it has on people who undergo tumor TAE as part of their regular care. Bumetanide is a commonly used medication to reduce the amount of water in the body.
Primary Outcome
Three escalating doses of bumetanide will be used: 0.01 mg/kg (level 1), 0.02 mg/kg (level 2) and 0.04 mg/kg (level 3) in a standard 3+3 design. Starting with level 1, three patients will first be enrolled at each level.
Conditions Studied
Interventions
- DRUG Bumetanide
- PROCEDURE Hepatic artery embolization (HAE)
Study Locations (5)
New Jersey
- Memorial Sloan Kettering Basking Ridge (Consent and follow-up only) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Consent and follow-up only) - Middletown
- Memorial Sloan Kettering Bergen (Consent and follow-up only) - Montvale
New York
- Memorial Sloan Kettering Westchester (Consent and follow-up only) - Harrison
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2017-04-05 |
| Est. Completion | 2026-04-05 |
| Phase | Phase 1 |
What the registry record for NCT03107416 still lists
NCT03107416 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 84-participant average among 12 other Unresectable Hepatocellular Carcinoma trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Unresectable Hepatocellular Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Bumetanide is the first listed.
NCT03107416 lists 5 locations in 2 states (New Jersey, New York).
Frequently Asked Questions
What is clinical trial NCT03107416 about?
NCT03107416 is a clinical study titled "Delivering a Diuretic Into the Liver Artery Followed by Plugging up the Artery to Starve Out Liver Cancer Cells". The purpose of this study is to test the safety of Bumetanide , at different doses to find out what effects, if any, it has on people who undergo tumor TAE as part of their regular care. Bumetanide is a commonly used medication to reduce the amount of water in the body.
What is the current status of trial NCT03107416?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 30 participants. The study started on 2017-04-05. Estimated completion is 2026-04-05.
What conditions does trial NCT03107416 study?
This clinical trial studies the following conditions: Unresectable Hepatocellular Carcinoma.
What interventions are being tested in trial NCT03107416?
The interventions under investigation include: Bumetanide (DRUG), Hepatic artery embolization (HAE) (PROCEDURE).
Who is sponsoring clinical trial NCT03107416?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03107416 being conducted?
This trial has 5 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Unresectable Hepatocellular Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03107416's enrollment target sits among peer trials
30 8th of 12 higher than 4 of 12 other Unresectable Hepatocellular Carcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Unresectable Hepatocellular Carcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Modified Immune Cells (Autologous Dendritic Cells) and a Vaccine (Prevnar) Combined With Immune Checkpoint Inhibition After High-Dose External Beam Radiation Therapy in Treating Patients With Unresectable Liver Cancer
RECRUITING · Phase 1
-
Atezolizumab+Bevacizumab+SBRT in Unresectable HCC
RECRUITING · Phase 1
-
Durvalumab and Tremelimumab After Radioembolization for the Treatment of Unresectable, Locally Advanced Liver Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant
RECRUITING · Phase 2
-
Regorafenib and Yttrium-90 Radioembolization for Unresectable Hepatocellular Carcinoma
RECRUITING · Phase 2
-
An Observational Study to Learn More About How Well a Treatment Works When Given After Treatment With Atezolizumab and Bevacizumab or Another Similar Combination of Drugs in Adults With Liver Cancer That Cannot be Treated With Surgery
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI